

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	D	4	3	4	1	5	3	11/21/00	Anderson <i>et al.</i>	D24	D216	04/20/98
	B	4	8	9	4	3	2	6	01/16/90	Matsuura <i>et al.</i>	435	7	04/09/86
	C	4	9	1	9	8	8	9	04/24/90	Jones <i>et al.</i>	422	40	09/15/88
	D	5	0	3	6	4	7	9	07/30/95	Prednis <i>et al.</i>	364	580	04/20/89
	E	5	0	9	1	1	7	0	02/25/92	Navot	424	9	04/06/89
	F	5	2	7	9	9	4	1	01/18/94	Lessey	435	7.21	06/12/92
	G	5	4	7	4	9	2	7	12/12/95	Anderson <i>et al.</i>	435	7.21	10/19/93
	H	5	4	8	0	7	7	6	01/02/96	Dullien	435	7.9	05/12/94
	I	5	6	2	3	9	3	9	04/29/97	Garfield	128	733	06/07/95
	J	5	6	5	0	3	9	4	07/22/97	Terao <i>et al.</i>	514	14	11/04/93
	K	6	2	6	7	7	2	2	07/31/01	Anderson <i>et al.</i>	600	300	02/03/98
	L	6	3	9	4	9	5	2	05/28/02	Anderson <i>et al.</i>	600	300	04/20/98

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	M	0	1	6	2	2	9	8	08/30/01 (A2)	PCT				
	N	0	3	1	6	9	1	9	07/06/95	EP				
	O	0	6	4	2	6	6	7	01/10/01	EP				
	P	6	1	1	9	2	9	1	04/28/94	JP			X	
	Q	9	2	1	0	5	8	5	06/25/92	PCT				
	R	9	3	0	9	4	3	2	05/13/93	PCT				
	S	9	3	2	4	8	3	6	12/09/93	PCT				
	T	9	3	2	4	8	3	8	12/09/93	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	U	9	4	1	7	4	0	5	08/04/94	PCT				
	V	9	4	2	7	4	9	0	12/08/94	PCT				
	W	9	5	1	2	4	0	6	05/11/95	PCT				
	X	9	6	0	3	9	2	9	02/15/96	PCT				
	Y	9	6	2	6	2	7	3	08/29/96	PCT				
	Z	9	7	2	9	4	4	7	08/14/97	PCT				
	AA	9	7	4	5	7	4	4	12/04/97	PCT				
	AB	9	9	0	9	5	0	7	02/25/99	PCT				
	AC	9	9	3	9	2	9	8	08/05/99	PCT				

X - English Translation being provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	Ahner <i>et al.</i> , "Fetal fibronectin as a selection criterion for induction of term labor", <i>Am. J. Obstet. Gynecol.</i> , <u>173</u> :1513-1517, 1995
AE	Allen <i>et al.</i> , "Help for high-risk pregnancies", San Jose Mercury News, February 7, 2003 edition
AF	Bailit <i>et al.</i> , "Reducing the caesarean delivery risk in elective inductions of labour: a decision analysis", <i>Pediatric and Perinatal Epidemiology</i> , <u>16</u> :90-96, 2002
AG	Blanch <i>et al.</i> , "The presence of fetal fibronectin in the cervicovaginal secretions of women at term - Its role in the assessment of women before labor induction and in the investigation of the physiologic mechanisms of labor", <i>Am. J. Obstet. Gynecol.</i> , <u>174</u> :262-266, 1996
AH	Breart <i>et al.</i> , "A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor", <i>Int. J. Gynaecol. Obstet.</i> , <u>16</u> :381-384, 1979
AI	Castellani <i>et al.</i> , "The fibronectin isoform containing the ED-B Oncofetal Domain: A Marker of Angiogenesis", <i>Int. J. Cancer</i> , <u>59</u> :612-618, 1994

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AJ	Citation 1: English translation and Japanese version of <u>Mitsubishi Electric Technical Report</u> , Vol. 68, No. 8, Special Edition on "Neural Network Application Technology", August 1994
AK	Citation 2: English Translation and Japanese version of <u>Personal Computer Statistical Analysis Handbook II Multivariate Analysis Edition</u> , Tanaka <i>et al.</i> , (Editors), November 1997
AL	Citation 3: English Translation of Japanese Patent No. 6-119291 (Cited at document D), published April 28, 1994, Kurokawa <i>et al.</i> , for "Water Supply Prediction Device"
AM	Citation 4: English Translation and Japanese version of <u>International Academic Society Article 1999-01322-004</u> , Bibliographic Item Printing, November 12, 2002
AN	Citation 5: English Translation and Japanese version of <u>International Academic Society Article 1999-00312-010</u> , Bibliographic Item Printing, November 12, 2002
AO	Creasy <i>et al.</i> , "Prevention of Preterm Birth", <i>Seminars in Perinatology</i> , <u>5(3)</u> :395-302, 1981
AP	Fuller, William E., "Management of Premature Labor", <i>Clinical Obstetrics and Gynecology</i> , <u>21(2)</u> :533-545, 1978
AQ	Garite <i>et al.</i> , "Fetal fibronectin: A new tool for the prediction of successful induction of labor", <i>Am. J. Obstet. Gynecol.</i> , <u>175</u> :1516-1521, 1996
AR	Goldstein <i>et al.</i> , "A meta-analysis of randomized control trials of progestational agents in pregnancy", <i>British J. Obstet. Gynecol.</i> , <u>96</u> :265-274, 1989
AS	Grady, Denise, "Hormone Cuts Risk of Premature Birth", <i>The New York Times</i> , February 7, 2003 Edition
AT	Gyetvai <i>et al.</i> , "Tocolytics for preterm labor: a systematic review", <i>Obstet. Gynecol.</i> , <u>94(5 Pt 2)</u> :869-877, 1999
AU	Halin <i>et al.</i> , "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", <i>Nature Biotechnology</i> , <u>20</u> :264-269, 2002
AV	Hartikainen-Sorri <i>et al.</i> , "Inefficacy of 17 α -Hydroxyprogesterone Caproate in the Prevention of Prematurity in Twin Pregnancy", <i>Obstet. Gynecol.</i> , <u>56(6)</u> :692-695, 1980
AW	Hauth <i>et al.</i> , "The effect of a 17 α -hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population", <i>Am. J. Obstet. Gynecol.</i> , <u>146</u> :187-190, 1983

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AX	Imai <i>et al.</i> , "Significance of fetal fibronectin and cytokine measurement in the cervicovaginal secretions of women at term in predicting term labor and post-term pregnancy", <i>European J. Obstet. Gynecol. Reprod. Biol.</i> , <u>97</u> :53-58, 2001
AY	Johnson <i>et al.</i> , "High-Risk Prematurity--Progestin Treatment and Steroid Studies", <i>Obstet. Gynecol.</i> , <u>54</u> (4):412-418, 1979
AZ	Johnson <i>et al.</i> , "Efficacy of 17 α -Hydroxyprogesterone aproate in the prevention of premature labor", <i>N. Eng. J. Med.</i> , <u>293</u> (14):675-680, 1975
BA	Kaczmarek <i>et al.</i> , "Distribution of Oncofetal Fibronectin Isoforms in Normal Hyperplastic and Neoplastic Human Breast Tissues", <i>Int. J. Cancer</i> , <u>58</u> :11-16, 1994
BB	Kahn <i>et al.</i> , "Preliminary Investigation of a Bayesian Network for Mammographic Diagnosis of Breast Cancer", <i>Proceedings of the 19th Annual Symposium on Computer Applications in Medical Care</i> , pp. 208-212 (1995)
BC	Kaupila <i>et al.</i> , "Suppression of threatened premature labor by administration of cortisol and 17 α -hydroxyprogesterone caproate: A comparison with ritodrine", <i>Am. J. Obstet. Gynecol.</i> , <u>138</u> :404-408, 1980
BD	Keirse <i>et al.</i> , "Progestogen administration in pregnancy may prevent preterm delivery", <i>Br. J. Obstet. Gynecol.</i> , <u>97</u> :149-154, 1990
BE	Kiss <i>et al.</i> , "Fetal fibronectin as a predictor of term labor: A literature review", <i>Acta Obstet. Gynecol. Scand.</i> , <u>79</u> :3-7, 2000
BF	Lockwood <i>et al.</i> , "Fetal Fibronectin in Cervical and Vaginal Secretions as a Predictor of Preterm Delivery", <i>New England J. of Medicine</i> , <u>325</u> (10):569-674, 1991
BG	Marty <i>et al.</i> , "Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes", <i>British J. Cancer</i> , <u>87</u> :106-112, 2002
BH	Reijnders <i>et al.</i> , "Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial", <i>Br. J. Obst. Gynaecol.</i> , <u>95</u> :462-468, 1988
BI	Rozenberg <i>et al.</i> , "Comparison of the Bishop score, ultrasonographically measured cervical length, and fetal fibronectin assay in predicting time until delivery and type of delivery at term", <i>Am. J. Obstet. Gynecol.</i> , <u>182</u> :108-113, 2002
BJ	Yemini <i>et al.</i> , "Prevention of premature labor by 17 α -hydroxyprogesterone caproate", <i>Am. J. Obstet. Gynecol.</i> , <u>151</u> :574-577, 1985

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	